Synaptogenix, Inc. (SNPX) Stock Ticker
Market factors today
Unlock the full SNPX picture
About Synaptogenix, Inc.
Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.
SNPX stock facts
| Ticker symbol | SNPX |
| Exchange | NASDAQ Capital Market |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $10.9M |
| CEO | Alan J. Tuchman MBA(FAAN) |
| Employees | 4 |
| Headquarters | New York City, NY, US |
| IPO date | 2020-12-08 |
| Website | www.synaptogen.com |
What you can see for SNPX on Tickr
Live SNPX price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the SNPX report.
Rankings
FAQ
What is the ticker symbol for Synaptogenix, Inc.?
The ticker symbol for Synaptogenix, Inc. is SNPX, listed on the NASDAQ Capital Market.
What is SNPX?
Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions,…